OA is the leading cause of chronic disability in older adults, costing the US more than $185 billion annually
Percentage of US adult population who were obese or severely obese in 2014, a significant risk factor for OA
No approved drugs can prevent, stop, or even slow the progression of OA
The global market for analgesics in Osteoarthritis is >$8bn and projected to reach $12.3bn by 2027, growing at a CAGR of 7.6%. Self medicated and prescribed analgesics have short term benefits due to diminishing efficacy. Steroid injections have only short term benefits.
Based upon pre-clinical and clinical data APPA has the potential to be a ground-breaking treatment for human and animal osteoarthritis.
APPA is the only NCE with a mechanism of action that targets the multiple signalling pathways in bone, cartilage and inflammation that results in inflammation, pain and loss of function in OA. In addtion APPA has shown it can slow the progression of OA as demonstrated in two animal species.
The APPA phase IIa trial was designed to assess the efficacy of APPA in subjects with varying degrees of osteoarthritis and to identify those who would benefit the most. In a predefined subgroup, patients with more severe disease benefited with a statistically significant improvement in pain vs placebo. A post-hoc analysis identified that patients with greater pain and with OA in both knees, also benefitted with a significant improvement with APPA vs placebo.
The recently completed phase IIb study Phase 2b demonstrated dose-dependent efficacy and an excellent safety profile. In patients with higher baseline pain, the dry powder formulation demonstrated robust efficacy, outperforming standard NSAIDs and approaching the efficacy of corticosteroids, supported by a clear dose-response relationship.
No competitor combines oral administration, multi-pathway activity, and a potential DMOAD1 effect. APPA occupies clear whitespace in the OA landscape. Pre-specified subgroup (WOMAC2>30) shows consistent, clinically meaningful effects across all endpoints — a ready-made Phase 3 enrichment strategy.
It is AKL’s intention to partner further development of APPA for human OA beyond the current program. A phase III program has been developed in outline and this will be finalised with the development partner.